37 related articles for article (PubMed ID: 38451429)
1. MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.
Madadjim R; An T; Cui J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612727
[TBL] [Abstract][Full Text] [Related]
2. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study.
Huang J; Gao G; Ge Y; Liu J; Cui H; Zheng R; Wang J; Wang S; Go VL; Hu S; Liu Y; Yang M; Sun Y; Shang D; Tian Y; Zhang Z; Xiang Z; Wang H; Guo J; Xiao GG
Dig Dis Sci; 2024 Apr; 69(4):1263-1273. PubMed ID: 38451429
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
4. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer.
Yu Y; Tong Y; Zhong A; Wang Y; Lu R; Guo L
Medicine (Baltimore); 2020 Dec; 99(52):e23863. PubMed ID: 33350781
[TBL] [Abstract][Full Text] [Related]
5. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer.
Liu J; Gao J; Du Y; Li Z; Ren Y; Gu J; Wang X; Gong Y; Wang W; Kong X
Int J Cancer; 2012 Aug; 131(3):683-91. PubMed ID: 21913185
[TBL] [Abstract][Full Text] [Related]
6. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis.
Seyed Salehi A; Parsa-Nikoo N; Roshan-Farzad F; Shams R; Fathi M; Asaszadeh Aghdaei H; Behmanesh A
Dis Markers; 2022; 2022():8040419. PubMed ID: 36254252
[TBL] [Abstract][Full Text] [Related]
8. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Cancer: A Review.
Park W; Chawla A; O'Reilly EM
JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of the microRNA-132 during tumor progressions.
Moghbeli M; Zangouei AS; Nasrpour Navaii Z; Taghehchian N
Cancer Cell Int; 2021 Aug; 21(1):439. PubMed ID: 34419060
[TBL] [Abstract][Full Text] [Related]
11. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review.
Yang J; Xu R; Wang C; Qiu J; Ren B; You L
Cancer Commun (Lond); 2021 Dec; 41(12):1257-1274. PubMed ID: 34331845
[TBL] [Abstract][Full Text] [Related]
12. Cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
